Pneumococcal disease prevention (vaccines): cross-border specialty drug access for international patients

Quick orientation

Streptococcus pneumoniae causes substantial morbidity and mortality globally, particularly in children under 5 and adults over 65. The burden is highest in low- and middle-income countries.

Typical age of onset. Any age. Vaccination schedules vary by jurisdiction and risk profile.

Severity tiers. Invasive pneumococcal disease (bacteremia, meningitis) is life-threatening. Otitis media and non-invasive pneumonia are far more common.

Why specialty drugs for Pneumococcal disease prevention (vaccines) are hard to access internationally

Capvaxive and other newer-generation conjugate vaccines (PCV20, PCV21) have expanded serotype coverage. Registration and supply outside high-income countries varies; cross-border supply has supported individual patients in some markets.

Treatments approved by the FDA

• Capvaxive (pneumococcal 21-valent conjugate vaccine) — FDA approval: 2024. Mechanism: 21-serotype pneumococcal conjugate vaccine for adults. Route: Intramuscular injection (single dose typically). US WAC ballpark: Approximately USD 250 to 350 per dose. Country pricing: Saudi Arabia.
• Enflonsia (clesrovimab-cfor) — FDA approval: 2025. Mechanism: Anti-RSV monoclonal antibody for infants (RSV prevention; complementary infant immunoprophylaxis). Route: Intramuscular injection. US WAC ballpark: Approximately USD 500 per dose. Country pricing: Jordan · Bahrain · Oman.

Cross-border pathways used for Pneumococcal disease prevention (vaccines)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm vaccination history.
• Document risk factors (age, comorbidities, immunocompromise).
• Cold-chain handling is critical for vaccines.
• Coordinate with treating physician or vaccination clinic.
• Some destination countries require national-program coordination for adult immunization.

Common questions

Is Capvaxive available in my country?

Registration is in early stages globally. We confirm by destination.

Does this replace PCV13 or PCV15?

Capvaxive is one of several newer adult pneumococcal vaccines; specific recommendations vary by national authority.

How is the cold chain handled?

Validated specialty couriers with continuous temperature monitoring.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Physician's prescription and vaccination history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Pneumococcal disease prevention (vaccines), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Pneumococcal disease prevention (vaccines)

Reserved for you.